For clinical application, our results raise the possibility that activators of CAR cell-specific RUNX1 can decrease bone marrow fibrosis, which might be applied to non-cell-autonomous therapies targeting the HSC niches, in hematological disorders, including MPN. The gene discussed is RUNX1; the disease is myeloproliferative disorder.